Abstract

Neurodegenerative disorders are common among the elderly. They possess a tremendous therapeutic challenge for drug development and tackling the disease. Alzheimer's ranks as the most common neurodegenerative disease affecting the elderly population. Developing therapeutics is still a challenge despite advancements in the medical sciences. Replacing the small molecules that are used for Alzheimer's today, numerous Monoclonal antibodies and vaccines are tried that targets explicitly the disease pathology, either beta-amyloid or Tau aggregation. In this review, we try to shed light on the existing small molecule therapeutics and the recent advances with insights into Monoclonal antibodies and clinical trials.